Abstract
Objective: The present study aims to describe the efficacy and safety of onabotulinum toxin A (BonT-A) with evaluation of treatment satisfaction and impact on quality of life in chronic migraine (CM) patients in real life. Methods: This study was conducted in CM patients who were treated with BoNT-A with 12 months of follow-up. Data about outcome, adverse events, and patients’ pre- and post-treatment status including health-related quality of life data were analyzed. Health-related quality of life scores were measured at baseline and months 6 and 12 after the beginning of BoNT-A administration. Results: Of 42 enrolled patients, 30 were included in the analysis. At 12 months, all patients showed a reduction in number of headaches and analgesic use per month and none reported adverse events. After BoNT-A supplementation, health-related quality-of-life scores improved significantly. There was a direct association between health-related quality of life with reduction of headache days at the end of study. Conclusion: This study confirms that BoNT-A treatment is effective on CM and improves the functional well-being and quality of life of patients.
References
1.
Headache Classification Committee of the International Headache Society
. The International Classification of Headache Disorders, 3rd edition
. Cephalalgia
. 2018
;38
:1
–211
.2.
Ching
J
, Tinsley
A
, Rothrock
J
. Prognosis following discontinuation of onabotulinuma therapy in “super-responding” chronic migraine patients
. Headache
. 2019
;59
(8
):1279
–85
. 3.
Bigal
ME
, Serrano
D
, Reed
M
, Lipton
RB
. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment
. Neurology
. 2008
;71
(8
):559
–66
. 4.
Dodick
DW
, Turkel
CC
, DeGryse
RE
, Aurora
SK
, Silberstein
SD
, Lipton
RB
, et al OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program
. Headache
. 2010
;50
(6
):921
–36
. 5.
Grazzi
L
, Usai
S
. Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience
. Neurol Sci
. 2015
;36
(Suppl 1
):33
–5
. 6.
Sandrini
G
, Tassorelli
C
, Sances
G
, Avenali
M
, Icco
RD
, Martinelli
D
, et al Botulinum toxin for chronic migraine: clinical trials and technical aspects
. Toxicon
. 2018
;147
:111
–5
.7.
Blumenfeld
A
, Silberstein
SD
, Dodick
DW
, Aurora
SK
, Turkel
CC
, Binder
WJ
. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well tolerated, and effective treatment paradigm based on the PREEMPT clinical program
. Headache
. 2010
;50
:1406
–18
.8.
Botox [package insert]. Irvine: Allergan plc; 2018
.9.
Dominguez
C
, Pozo-Rosich
P
, Torres-Ferrús
M
, Hernández-Beltrán
N
, Jurado-Cobo
C
, Gonzalez-Oria
C
, et al OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study
. Eur J Neurol
. 2018
;25
(2
):411
–6
.10.
Sandrini
G
, Perrotta
A
, Tassorelli
C
, Torelli
P
, Brighina
F
, Sances
G
, et al Botulinm toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study
. J Headache Pain
. 2011
;12
(4
):427
–33
.11.
Young
WB
, Ivan Lopez
J
, Rothrock
JF
, Orejudos
A
, Manack Adams
A
, Lipton
RB
, et al Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study
. J Headache Pain
. 2019
;20
(1
):12
. 12.
Beckmann
YY
, Seçil
Y
, Kendir
AI
, Başoğlu
M
. Chronic migraine: a prospective descriptive clinical study in a headache center population
. Pain Pract
. 2009
;9
(5
):380
–4
. 13.
Martinelli
D
, Arceri
S
, Tronconi
L
, Tassorelli
C
. Chronic migraine and botulinum toxin type A: where do paths cross?
Toxicon
. 2020
;178
:69
–76
. 14.
Buse
DC
, Manack
AN
, Fanning
KM
, Serrano
D
, Reed
ML
, Turkel
CC
, et al Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study
. Headache
. 2012
;52
(10
):1456
–70
. 15.
Andrasik
F
, Grazzi
L
, Usai
S
, Kass
S
, Bussone
G
. Disability in chronic migraine with medication overuse: treatment effects through 5 years
. Cephalalgia
. 2010
;30
(5
):610
–4
. 16.
Buse
D
, Manack
AN
, Fanning
KM
, Serrano
D
, Reed
ML
, Turkel
CC
, et al Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention Study
. Headache
. 2012
;52
(1
):3
–17
.17.
Burstein
R
, Noseda
R
, Borsook
D
. Migraine: multiple processes, complex pathophysiology
. J Neurosci
. 2015
;35
(17
):6619
–29
. 18.
Boyer
N
, Dallel
R
, Artola
A
, Monconduit
L
. General trigeminospinal central sensitization and impaired descending pain inhibitory controls contribute to migraine progression
. Pain
. 2014
;155
(7
):1196
–205
. 19.
Goadsby
PJ
, Holland
PR
, Martins-Oliveira
M
, Hoffmann
J
, Schankin
C
, Akerman
S
. Pathophysiology of migraine: a disorder of sensory processing
. Physiol Rev
. 2017
;97
(2
):553
–622
. 20.
Agostoni
EC
, Barbanti
P
, Calabresi
P
, Colombo
B
, Cortelli
P
, Frediani
F
, et al Current and emerging evidence-based treatment options in chronic migraine: a narrative review
. J Headache Pain
. 2019
;20
(1
):92
. 21.
Frampton
JE
, Silberstein
S
. OnabotulinumtoxinA: a review in the prevention of chronic migraine
. Drugs
. 2018
;78
(5
):589
–600
. 22.
Mathew
NT
, Jaffri
SF
. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study
. Headache
. 2009
;49
(10
):1466
–78
. 23.
Rothrock
JF
, Adams
AM
, Lipton
RB
, Silberstein
SD
, Jo
E
, Zhao
X
, et al Forward study: evaluating the comparative effectiveness of OnabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine
. Headache
. 2019
;59
(10
):1700
–13
. 24.
Winner
PK
, Blumenfeld
AM
, Eross
EJ
, Orejudos
AC
, Mirjah
DL
, Adams
AM
, et al Long‐term safety and tolerability of OnabotulinumtoxinA treatment in patients with chronic migraine: results of the COMPEL Study
. Drug Saf
. 2019
;42
(8
):1013
–24
. © 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
